Achelois BioPharma develops curative, programmable Multivalent Therapeutics to treat cancer, viral infection, autoimmune, and inflammatory diseases. Unlike traditional drugs, which are designed to target a single molecule, multivalent therapeutics are designed to target a combination of molecules underlying complex human diseases. The Autocloner application assists scientists to discover and develop these novel treatments.